Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan

This episode of the Gastrointestinal Cancer Update podcast features Dr. Neil Love interviewing Dr. Ravin Ratan from MD Anderson Cancer Center on the practical management of desmoid tumors, focusing on real-world case discussions. The conversation centers on three complex patient cases: a 40-year-old woman with a large pelvic desmoid who experienced spontaneous regression on active surveillance; a 39-year-old with a symptomatic intra-abdominal desmoid that responded dramatically to niragacostat; and a 41-year-old with recurrent breast desmoid after multiple surgeries and radiation, who achieved sustained remission with systemic therapy. Dr. Ratan emphasizes that not all desmoid tumors require treatment, surgery is no longer the first-line approach due to high recurrence rates, and systemic therapies like niragacostat offer effective alternatives with manageable side effects. He discusses the timing of treatment response—symptoms often improve quickly, while imaging shrinkage lags—and highlights the lack of definitive guidelines on treatment duration, recommending a minimum of six months to a year, with discontinuation possible if the tumor remains stable and symptoms are controlled. The episode also explores the impact of ovarian suppression from targeted therapies, the role of cryoablation in select cases, and the importance of multidisciplinary care. Overall, the discussion underscores a shift toward personalized, non-surgical management strategies based on symptom burden and tumor location rather than size alone. Key takeaways include: 1) Active surveillance is viable for select patients, especially those with large tumors and fertility concerns; 2) Systemic therapies like niragacostat can lead to rapid symptom relief and significant tumor shrinkage; 3) Treatment duration should be time-limited and individualized, with discontinuation considered after 1–2 years if stable; 4) Cryoablation is a promising local option for accessible tumors, though residual findings post-treatment require careful interpretation; 5) Ovarian toxicity from targeted agents is likely reversible but not fully predictable, warranting fertility counseling; 6) Prior surgery or radiation does not preclude response to systemic therapy; 7) Patient-centered decision-making is essential, especially when balancing treatment efficacy with quality of life; 8) Multidisciplinary consultation is strongly advised for complex cases.